EP4023225A4 - Composition used for combating metabolic diseases and uses of composition - Google Patents
Composition used for combating metabolic diseases and uses of composition Download PDFInfo
- Publication number
- EP4023225A4 EP4023225A4 EP20856770.1A EP20856770A EP4023225A4 EP 4023225 A4 EP4023225 A4 EP 4023225A4 EP 20856770 A EP20856770 A EP 20856770A EP 4023225 A4 EP4023225 A4 EP 4023225A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- metabolic diseases
- combating
- composition used
- combating metabolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030159 metabolic disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019103677 | 2019-08-30 | ||
PCT/CN2020/112143 WO2021037212A1 (en) | 2019-08-30 | 2020-08-28 | Composition used for combating metabolic diseases and uses of composition |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4023225A1 EP4023225A1 (en) | 2022-07-06 |
EP4023225A4 true EP4023225A4 (en) | 2023-08-30 |
Family
ID=74683374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20856770.1A Pending EP4023225A4 (en) | 2019-08-30 | 2020-08-28 | Composition used for combating metabolic diseases and uses of composition |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220323408A1 (en) |
EP (1) | EP4023225A4 (en) |
JP (1) | JP2022546987A (en) |
KR (1) | KR20220054351A (en) |
CN (1) | CN114364385A (en) |
AU (1) | AU2020339557A1 (en) |
CA (1) | CA3152868A1 (en) |
IL (1) | IL290927A (en) |
WO (1) | WO2021037212A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023504547A (en) * | 2019-12-05 | 2023-02-03 | フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド | Acylated active agents and methods of their use for the treatment of metabolic disorders and non-alcoholic fatty liver disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5127093B1 (en) | 1970-11-11 | 1976-08-10 | ||
AU570112B2 (en) | 1984-04-02 | 1988-03-03 | Cornell Research Foundation Inc. | Aminocarnitines |
HUT65327A (en) | 1992-06-11 | 1994-05-02 | Sandoz Ag | Process for producing phosphinyloxy-propyl-ammonium inner sact derwatives ang pharmateutical preparations containing them |
IT1299266B1 (en) | 1998-05-15 | 2000-02-29 | Sigma Tau Ind Farmaceuti | REVERSIBLE CARNITINE PALMITOIL INHIBITORS TRANSFERRED |
GB2462947A (en) * | 2007-03-09 | 2010-03-03 | Symcopeia Company | Fatty Acid Oxidation Inhibitors Treating Hyperglycemia and Related Disorders. |
US20110275649A1 (en) * | 2010-05-05 | 2011-11-10 | Palmetto Pharmaceuticals Llc | Combination therapy for the prevention of statin induced diabetes |
BR112013016021A2 (en) * | 2010-12-21 | 2018-12-11 | Nestec Sa | Appropriate methods and compositions for managing blood glucose in animals |
-
2020
- 2020-08-28 CN CN202080060415.1A patent/CN114364385A/en active Pending
- 2020-08-28 WO PCT/CN2020/112143 patent/WO2021037212A1/en active Application Filing
- 2020-08-28 AU AU2020339557A patent/AU2020339557A1/en active Pending
- 2020-08-28 JP JP2022513603A patent/JP2022546987A/en active Pending
- 2020-08-28 EP EP20856770.1A patent/EP4023225A4/en active Pending
- 2020-08-28 US US17/639,181 patent/US20220323408A1/en active Pending
- 2020-08-28 KR KR1020227009807A patent/KR20220054351A/en unknown
- 2020-08-28 CA CA3152868A patent/CA3152868A1/en active Pending
-
2022
- 2022-02-27 IL IL290927A patent/IL290927A/en unknown
Non-Patent Citations (2)
Title |
---|
MONTI LUCILLA D ET AL: "Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy", AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOLISM, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 290, no. 1, 20 September 2005 (2005-09-20), pages E54 - E59, XP008092383, ISSN: 0193-1849, DOI: 10.1152/AJPENDO.00083.2005 * |
REDDY PRIYA ET AL: "Metabolic syndrome is an inflammatory disorder: A conspiracy between adipose tissue and phagocytes", CLINICA CHIMICA ACTA, vol. 496, 20 June 2019 (2019-06-20), AMSTERDAM, NL, pages 35 - 44, XP093066678, ISSN: 0009-8981, DOI: 10.1016/j.cca.2019.06.019 * |
Also Published As
Publication number | Publication date |
---|---|
EP4023225A1 (en) | 2022-07-06 |
IL290927A (en) | 2022-04-01 |
KR20220054351A (en) | 2022-05-02 |
WO2021037212A9 (en) | 2022-03-24 |
JP2022546987A (en) | 2022-11-10 |
WO2021037212A1 (en) | 2021-03-04 |
CA3152868A1 (en) | 2021-03-04 |
AU2020339557A1 (en) | 2022-03-24 |
CN114364385A (en) | 2022-04-15 |
US20220323408A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3841090A4 (en) | Specially formulated compositions of inhaled nintedanib and nintedanib salts | |
EP3740576A4 (en) | Therapeutic compositions and methods of making and using the same | |
EP3829307A4 (en) | Bismuth-thiol compositions and methods of use | |
EP3915998A4 (en) | Application of salidroside derivative in skin-whitening agent for external use | |
EP3737379A4 (en) | Compositions and methods for treating metabolic diseases | |
EP4073071A4 (en) | Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives | |
EP3930704A4 (en) | Compositions including cinnamic acid and methods of use thereof | |
EP3793563A4 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
EP3917910A4 (en) | Therapeutic compounds and compositions | |
EP3969597A4 (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
EP3873444A4 (en) | Therapeutic compounds and compositions | |
EP3866852A4 (en) | Compositions and methods for treatment of liver disease | |
EP3790552A4 (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
EP4045071A4 (en) | Curcuminoid composition for therapeutic management of metabolic syndrome | |
IL290927A (en) | Composition used for combating metabolic diseases and uses of composition | |
EP4031520A4 (en) | Imaging and therapeutic compositions | |
EP4039768A4 (en) | Composition of fluoroolefin and fluoroalkane | |
EP3946318A4 (en) | Extended release composition of tofacitinib | |
EP3873446A4 (en) | Therapeutic compounds and compositions | |
EP3810118A4 (en) | Formulations of tegavivint and related compounds | |
EP3952924A4 (en) | Compositions and methods for administration of therapeutics | |
EP3877383A4 (en) | Compounds and compositions for the treatment of respiratory diseases | |
EP3904356A4 (en) | Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound | |
EP4054514A4 (en) | Compositions containing fenchols and methods of use | |
EP4034130A4 (en) | Pharmaceutical compounds and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220329 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40071125 Country of ref document: HK |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230801 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 43/00 20060101ALI20230726BHEP Ipc: A61P 27/06 20060101ALI20230726BHEP Ipc: A61P 27/00 20060101ALI20230726BHEP Ipc: A61P 9/10 20060101ALI20230726BHEP Ipc: A61P 3/06 20060101ALI20230726BHEP Ipc: A61P 3/04 20060101ALI20230726BHEP Ipc: A61P 1/16 20060101ALI20230726BHEP Ipc: A61P 3/00 20060101ALI20230726BHEP Ipc: A61K 45/06 20060101ALI20230726BHEP Ipc: A61K 31/495 20060101ALI20230726BHEP Ipc: A61K 31/616 20060101AFI20230726BHEP |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 43/00 20060101ALI20230811BHEP Ipc: A61P 27/06 20060101ALI20230811BHEP Ipc: A61P 27/00 20060101ALI20230811BHEP Ipc: A61P 9/10 20060101ALI20230811BHEP Ipc: A61P 3/06 20060101ALI20230811BHEP Ipc: A61P 3/04 20060101ALI20230811BHEP Ipc: A61P 1/16 20060101ALI20230811BHEP Ipc: A61P 3/00 20060101ALI20230811BHEP Ipc: A61K 45/06 20060101ALI20230811BHEP Ipc: A61K 31/495 20060101ALI20230811BHEP Ipc: A61K 31/616 20060101AFI20230811BHEP |